Skip to main content

Gillette treats more than 4,000 children each year who have cerebral palsy. We have a depth of experience treating all types of cerebral palsy, from mild to severe. This knowledge drives our research efforts, which in turn helps us to improve treatment for children around the world who have cerebral palsy.


Long-Term Selective Dorsal Rhizotomy Outcomes

Led by Nanette Aldahondo, MD:

Our Center for Gait and Motion Analysis actively measures and publishes short-term treatment outcomes. There is, however, almost no data from any gait and motion center documenting long-term outcomes of treatments. This study examines the long-term effects of treatments for cerebral palsy—a comparison of selective dorsal rhizotomy (SDR) surgery to standard cerebral palsy treatments without SDR. This study examines matched cohorts of patients in early adulthood and assesses important factors such as pain, function and quality of life.


Intrathecal Baclofen Pump Research

Led by Michael Partington, MD:

  • Intrathecal Baclofen Pump Outcomes.

Led by Patrick Graupman, MD:

  • Bed Rest After Intrathecal Baclofen Pump Implantation.
  • Brandenburg JE, Krach LE, Gormley ME Jr. Use of rimabotulinum toxin for focal hypertonicity management in children with cerebral palsy with nonresponse to onabotulinum toxin. Am J Phys Med Rehabil. 2013 Oct;92(10):898-904. doi: 10.1097/PHM.0b013e31829231fa. PMID: 23636084
  • Cameron NA, Gormley ME Jr, Deshpande S. Severity of disability in patients with cerebral palsy secondary to symptomatic congenital cytomegalovirus encephalopathy. J Pediatr Rehabil Med. 2013 Jan 1;6(4):239-42. doi: 10.3233/PRM-140258. PMID: 24705659